mutated Ligand Binding Site gene DataBase





About Us

Bioinformatics and Systems Medicine Laboratory Bioinformatics and Systems Medicine Laboratory

Gene Summary

Ligand Binding Site Mutation Information

Protein Structure Related Information

Gene Expression and Gene-Gene Network

Phenotype Information

Pharmacological Information

Conservation Information for LBS

Gene summary for RNASE2
Gene summary
Basic gene Info.Gene symbolRNASE2
Gene nameribonuclease, RNase A family, 2 (liver, eosinophil-derived neurotoxin)
CytomapUCSC genome browser: 14q11.2
Type of geneprotein-coding
DescriptionRNase 2RNase UpI-2eosinophil-derived neurotoxinnon-secretory ribonucleaseribonuclease 2ribonuclease A F3ribonuclease US
Modification date20141207
dbXrefs MIM : 131410
Ensembl : ENSG00000169385
HPRD : 00577
Vega : OTTHUMG00000029607
ProteinUniProt: P10153
go to UniProt's Cross Reference DB Table
ExpressionCleanEX: HS_RNASE2
BioGPS: 6036
PathwayNCI Pathway Interaction Database: RNASE2
Pathway Commons: RNASE2
ContextiHOP: RNASE2
ligand binding site mutation search in PubMed: RNASE2
UCL Cancer Institute: RNASE2
Assigned class in mutLBSgeneDBC: This gene just belongs to mutLBSgenes.

Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez

Ligand binding site mutations for RNASE2

Cancer type specific mutLBS sorted by frequency
LBSAAchange of nsSNVCancer type# samples
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma.

Protein structure related information for RNASE2
Relative protein structure stability change (ΔΔE) using Mupro 1.1
Mupro score denotes assessment of the effect of mutations on thermodynamic stability.
  (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability)
: nsSNV at non-LBS: nsSNV at LBS

nsSNVs sorted by the relative stability change of protein structure by each mutation
Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene.
LBSAAchange of nsSNVRelative stability change
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132)

Structure image for RNASE2 from PDB

Differential gene expression and gene-gene network for RNASE2
Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types

Differential co-expressed gene network based on protein-protein interaction data (CePIN)
* Left PPI network was created from samples with mutations in the LBS of RNASE2 and the right PPI network was created from samples without mutations in the LBS of RNASE2. Only genes with p-value < 0.05 are shown.
Red circle: input gene. Orange circle: LBSgene. Blue circle: other gene.


Phenotype information for RNASE2
Gene level disease information (DisGeNet)
Disease IDDisease name# PubMedAssociation type
umls:C0017661Glomerulonephritis, IGA1Biomarker

Mutation level pathogenic information (ClinVar annotation)
Allele IDAA changeClinical significanceOriginPhenotype IDs

Pharmacological information for RNASE2
Gene expression profile of anticancer drug treated cell-lines (CCLE)
Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient.

Gene-centered drug-gene interaction network
Drug information targeting mutLBSgene (Approved drugs only)
Drug statusDrugBank IDNameTypeDrug structure
ExperimentalDB01812Adenosine-3'-5'-DiphosphateSmall molecule
ExperimentalDB02098Adenosine-2'-5'-DiphosphateSmall molecule

Gene-centered ligand-gene interaction network

Ligands binding to mutated ligand binding site of RNASE2 go to BioLip
Ligand IDLigand short nameLigand long namePDB IDPDB namemutLBS

Conservation information for LBS of RNASE2
Multiple alignments for P10153 in multiple species
LBSAA sequence# speciesSpecies
A137MFYIVACDNRD2Homo sapiens, Pan troglodytes
A137KSYTVACNPRT1Mus musculus
C89NPNMTCPSNKT2Homo sapiens, Pan troglodytes
C89NPPKTC-KDGT1Mus musculus
D139YIVACDNRDQR2Homo sapiens, Pan troglodytes
D139YTVACNPRTP-1Mus musculus
D158VPVHLDRII2Homo sapiens, Pan troglodytes
D158VPVHLDRLF1Mus musculus
H109QVPLIHCNLTT2Homo sapiens, Pan troglodytes
H109KVSVTICKLTK1Mus musculus
H156PVVPVHLDRII2Homo sapiens, Pan troglodytes
H156PVVPVHLDRLF1Mus musculus
H42WFETQHI-NMT2Homo sapiens, Pan troglodytes
H42KFDIQHIYKKS1Mus musculus
K28GSLHVKPPQFT2Homo sapiens, Pan troglodytes
K28VSCQRPTP---1Mus musculus
K65YQRRCKNQNTF2Homo sapiens, Pan troglodytes
K65YTGKCKDLNTF1Mus musculus
L157VVPVHLDRII2Homo sapiens, Pan troglodytes
L157VVPVHLDRLF1Mus musculus
N66QRRCKNQNTFL2Homo sapiens, Pan troglodytes
N66TGKCKDLNTFL1Mus musculus
N97NKTRKNCHHSG1Homo sapiens
N97DGTSPNCHDSS1Mus musculus
N97NKTRKNCHQSG1Pan troglodytes
Q41QWFETQHI-NM2Homo sapiens, Pan troglodytes
Q41QKFDIQHIYKK1Mus musculus
Q67RRCKNQNTFLL2Homo sapiens, Pan troglodytes
Q67GKCKDLNTFLH1Mus musculus
R63NNYQRRCKNQN2Homo sapiens, Pan troglodytes
R63NKYTGKCKDLN1Mus musculus
R95PSNKTRKNCHH1Homo sapiens
R95-KDGTSPNCHD1Mus musculus
R95PSNKTRKNCHQ1Pan troglodytes
V155YPVVPVHLDRI2Homo sapiens, Pan troglodytes
V155YPVVPVHLDRL1Mus musculus
W34PPQFTWAQWFE2Homo sapiens, Pan troglodytes
W34TP----SQKFD1Mus musculus

Copyright © 2016-Present - The University of Texas Health Science Center at Houston
Site Policies | State of Texas